VYYRF Stock Chart & Stats
$0.13
>-$0.01(-10.37%)
At close: 4:00 PM EST
$0.13
>-$0.01(-10.37%)
Day’s Range― - ―
52-Week Range$0.01 - $0.24
Previous CloseN/A
Volume200.00
Average Volume (3M)5.52K
Market Cap
$15.78M
Enterprise Value$17.01M
Total Cash (Recent Filing)$75.71K
Total Debt (Recent Filing)$40.00K
Price to Earnings (P/E)―
Beta-19.77
Next Earnings
Aug 03, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding179,475,860
10 Day Avg. Volume7,500
30 Day Avg. Volume5,516
Financial Highlights & Ratios
PEG Ratio-0.11
Price to Book (P/B)21.82
Price to Sales (P/S)2339.21
P/FCF Ratio-9.45
Enterprise Value/Market Cap1.08
Enterprise Value/Revenue549.58
Enterprise Value/Gross Profit-12.61
Enterprise Value/Ebitda-5.09
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low LeverageLow debt reduces refinancing and interest-rate vulnerability while Voyageur scales commercialization. This preserves financial optionality to raise growth capital or absorb setbacks, giving the company durable runway to develop products without immediate solvency pressure.
Strong Revenue RampA ~165% TTM revenue increase signals meaningful commercialization progress and market traction for the firm's products. Sustained top-line growth can drive scale efficiencies over months, enabling potential margin recovery and improved operating leverage if costs are controlled.
Specialized Product NicheConcentrating on mineral-derived barium sulfate for medical and specialty uses creates a differentiated, technically demanding niche. Qualification, processing know-how, and regulatory barriers can form a durable competitive moat if the company successfully commercializes its supply.
Bears Say
Deep UnprofitabilityPersistent negative gross profit and large operating losses indicate the core economics are currently unviable. Continued unprofitability erodes reserves, delays self-sustaining cash generation, and forces reliance on financing until structural margins are demonstrably positive.
Negative Cash Flow / BurnSustained negative operating and free cash flow implies ongoing cash burn and a dependence on external funding. This creates execution risk over months as financing availability, terms, or dilution pressure could constrain the firm's ability to complete qualification or scale production.
Eroding Equity And Negative ROEDeclining equity and negative ROE reflect capital erosion from losses, reducing financial flexibility. Over the medium term this weakens the balance sheet's ability to absorb shocks or fund growth organically, increasing future financing or dilution risk.
Voyageur Pharmaceuticals News
VYYRF FAQ
What was Voyageur Pharmaceuticals’s price range in the past 12 months?
Voyageur Pharmaceuticals lowest stock price was $0.01 and its highest was $0.24 in the past 12 months.
What is Voyageur Pharmaceuticals’s market cap?
Voyageur Pharmaceuticals’s market cap is $15.78M.
When is Voyageur Pharmaceuticals’s upcoming earnings report date?
Voyageur Pharmaceuticals’s upcoming earnings report date is Aug 03, 2026 which is in 32 days.
How were Voyageur Pharmaceuticals’s earnings last quarter?
Currently, no data Available
Is Voyageur Pharmaceuticals overvalued?
According to Wall Street analysts Voyageur Pharmaceuticals’s price is currently Overvalued.
Does Voyageur Pharmaceuticals pay dividends?
Voyageur Pharmaceuticals does not currently pay dividends.
What is Voyageur Pharmaceuticals’s EPS estimate?
Voyageur Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Voyageur Pharmaceuticals have?
Voyageur Pharmaceuticals has 179,475,860 shares outstanding.
What happened to Voyageur Pharmaceuticals’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Voyageur Pharmaceuticals?
Currently, no hedge funds are holding shares in VYYRF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Voyageur Pharmaceuticals
Voyageur Pharmaceuticals Ltd. specializes in the creation of mineral-based active pharmaceutical ingredients (APIs). The company aims to produce radiocontrast agents utilizing barium and iodine, along with pharmaceutical products derived from bromine. It possesses complete ownership of three barium sulfate deposits in British Columbia, Canada, two of which are of a quality appropriate for the pharmaceutical barite sector. Furthermore, Voyageur holds stakes in a valuable brine project in Utah, United States, known for its high concentrations of iodine, lithium, and bromine. The company transitioned from its previous name, Voyageur Minerals Ltd., to Voyageur Pharmaceuticals Ltd. in December 2019. Its corporate headquarters are located in Calgary, Canada.
Technical Analysis
Ownership Overview
Options Prices
Currently, No data available
---